title: [Cardiac dysfunction induced by trastuzumab].
abstract: Trastuzumab combined to chemotherapy had demonstrated significant improvement of time to progression and survival in metastatic breast cancer patient overexpressing HER-2. Cardiac toxicity was an unexpected side effect. The incidence of cardiac dysfunction was dependent on prior or current anthracycline exposure. The mechanism of action involved for this cardiac toxicity is unclear. We discuss in this article the incidence, the physiopathology, the risk factors, the predictive factors and the patient management and on cardiotoxicity of trastuzumab.
authors.affiliation: Centre René-Gauducheau, Boulevard Jacques-Monod, 44805 Nantes Cedex. m-campone@nantes.fnclcc.fr
authors.forename: Mario
authors.initials: M
authors.lastname: Campone
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Bourbouloux
authors.forename: Pierre
authors.initials: P
authors.lastname: Fumoleau
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab